Clinical Trial Update: Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Fortelyzin (recombinant nonimmunogenic staphylokinase) with bolus infusion alteplase in acute ischemic stroke. Results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Alteplase (alteplase)
• Fortelyzin (staphylokinase, recombinant, nonimmunogenic)

Snippet

Sponsor: Supergene, LLC | Conditions: Ischemic Stroke | Phase 3 | Status: COMPLETED | Results posted: 2025-04-02